Amino Acids

, Volume 13, Issue 2, pp 171–181 | Cite as

Synthesis of salicyl-peptides and their effect on human platelet aggregationin vitro

  • G. Stavropoulos
  • V. Magafa
  • M. Liakopoulou-Kyriakides
  • Z. Sinakos
  • A. Aaberg
Full Papers


A series of leucine dipeptide amides containing at their N-terminal amino group the salicyl-residue [(o)-RO-C6H4-CO-, where R=H or CH3CO] have been synthesized by conventional solution techniques and tested for their inhibitory activity on human platelet aggregationin vitro induced by collagen, ADP or adrenaline. The salicyl-peptide (o)-HO-C6H4-CO-Leu-Asp(OBzl)-NH2 was found to exert strong inhibitory activity on platelet aggregation induced by collagen with an IC50 value 4.5 mM. The corresponding dipetide H2N-Leu-Asp(OVzl)-NH2 was also examined and was found to be less active, indicating that the presence of the lipophilicβ-benzyl ester group in combination with the salicyl group enhance the inhibitory activity. All the other salicyl-peptides examined either didn't show any inhibitory or aggregatory activity or a slight inhibition at the concentration of 9–10 mm.


Amino acids Collagen Inhibitory activity Platelet aggregation Salicyl-peptides 


The abbreviations used are in accordance with the rules of IUPAC-IUB Joint Commission on Biochemical Nomenclature: Eur J Biochem (1984) 138: 9–37; J Biol Chem (1989) 264: 663–673. Additional abbreviations are:


adenosine diphosphate








dimethyl sulfoxide




ethyl acetate


flash column chromatography


molar concentration of salicyl-peptide for 50% inhibition of platelet aggregation


isobutyl chloroformate




(benzotriazol-1-yloxy) tripyrrolidinophosphonium hexafluorophosphate


thin layer chromatography




Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baenziger NL, Dillender MJ, Majerus PW (1977) Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglantin. Bioch Bioph Res Comm 78: 294–301Google Scholar
  2. Born GVR (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194: 927–929PubMedGoogle Scholar
  3. Callahan JF et al (1992) Design and synthesis of a C7 mimetic for the predictedy-turn conformation found in several constrained RGD antagonists. J Med Chem 35: 3970–3972PubMedGoogle Scholar
  4. Coste J, Le-Nguyen D, Castro B (1990) Oxybenzotriazole free peptide coupling reagents for N-methylated amino acids. Tetrahedron Let 32: 205–208Google Scholar
  5. Das J, Kimball SD (1995) Thrombin active site inhibitors. Bioorg Med Chem 3: 999–1007PubMedGoogle Scholar
  6. Gartner TK, Bennett JS (1985) The tetrapeptide analogue of the cell attachment site of fibronenctin inhibits platelet aggregation and fibrinogen binding to activated platelets. J Biol Chem 260: 11891–11894PubMedGoogle Scholar
  7. Karagiannis K, Stavropoulos G, Poulos C, Jordan CC, Hagan RM (1993) Synthesis of a potent antagonist of Substance P by replacing the CH2SCH3 and the α-carboxamide groups of the methionine at [Orn6]-SP6–11 by benzyl ester groups. Int J Peptide Protein Res 42: 565–569Google Scholar
  8. Krstenansky JL, Mao SJT (1987) Antithrombin properties of C-terminus of hirudin using synthetic unsulfated Nα-acetyl-hirudin45–65. FEBS Let 211: 10–16Google Scholar
  9. Ku TW et al (1993) Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of highly constrained cyclic RGD peptide. J Am Chem Soc 115: 8861–8862Google Scholar
  10. Liakopoulou-Kyriakides M, Stavropoulos G, Karagiannis C, Calogridis P, Sinakos Z (1990) Effect of Leu-(Asp, Asn, Glu, Gln) dipeptides on platelet aggregationin vitro. Biochem Int 22: 617–625PubMedGoogle Scholar
  11. Liakopoulou-Kyriakides M, Stavropoulos G (1992) Effect of X-Asp (or Asn)-Phe-NH2 (Where X; H, Met) peptides on human platelet aggregationin vitro. Biochem Int 26: 249–256PubMedGoogle Scholar
  12. Muramatsu R, Komatsu Y, Nukui E, Okayama T, Morikawa T, Kobashi K, Hayashi H, (1996) Structure-activity studies on C-terminal hirudin peptides containing sulfated tyrosine residues. Int J Peptide Protein Res 48: 167–173Google Scholar
  13. Nishino N, Hayashida J, Arai T, Mihara H, Ueno Y, Kumagai H (1996) Cyclo(-arginylsarcosyl-aspartyl-phenylglycyl)2. Simple synthesis of an RGD-related peptide with inhibitory activity for platelet aggregation. J Chem Soc Perkin 1: 939–946Google Scholar
  14. Ojima I, Chakravarty S, Dong Q (1995) Antithrombotic agents: from RGD to peptide mimetics. Bioorg Med Chem 3: 337–360PubMedGoogle Scholar
  15. Owen TJ, Krstenansky JL, Yates MT, Mao SJT (1988) N-Terminal requirements of small peptide anticoagulants based on hirudin54–65. J Med Chem 31: 1009–1011PubMedGoogle Scholar
  16. Pierschbacher MD, Ruoslahti E (1984) Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309: 30–33PubMedGoogle Scholar
  17. Ruoslahti E, Pierschbacher MD (1987) New perspectives in cell adhesion: RGD and integrins. Science 238: 491–497PubMedGoogle Scholar
  18. Weiss HJ, Aledort LM (1967) Impaired platelet/connective-tissue reaction in man after aspirin ingestion. Lancet ii: 495–497Google Scholar
  19. Witting JI, Bourdon P, Brezniak DV, Maraganore JM, Fenton JW (1992) Thrombinspecific inhibition by and slow clevage of hirulog-1. Biochem J 283: 737–743PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • G. Stavropoulos
    • 1
  • V. Magafa
    • 1
  • M. Liakopoulou-Kyriakides
    • 2
  • Z. Sinakos
    • 3
  • A. Aaberg
    • 4
  1. 1.Department of ChemistryUniversity of PatrasPatrasGreece
  2. 2.Department of Chemical EngineeringUniversity of ThessalonikiGreece
  3. 3.Section of Hematology, Department of MedicineUniversity of ThessalonikiGreece
  4. 4.Department of ChemistryUniversity of BergenNorway

Personalised recommendations